Bristol Myers Squibb™

Investigational Trials of Iberdomide (CC-220) in Patients With Aggressive B-Cell Lymphomas

CC-220-DLBCL-001

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of Iberdomide (CC-220) and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Poor Risk (IPI 3–5), Aggressive B-Cell Lymphoma[1]

Enrolling soon — *NCT04884035* — *Phase 1b*

PRIMARY ENDPOINTS
MTD, RP2D, and safety and tolerability

SECONDARY ENDPOINTS
ORR, CMRR, TTR, DoR, PFS, OS, incidence of AEs, and PK

KEY ELIGIBILITY CRITERIA

De novo, previously untreated, aggressive BCL according to 2016 WHO classification

IPI score ≥3 (high-intermediate or high risk)

Measurable disease defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (>1.5 cm in longest diameter) disease by CT or MRI, as defined by the Lugano classification system

ECOG PS ≤2

TREATMENT *Estimated N=76*

FOLLOW-UP

Incidence of AEs

ORR, CMRR, TTR, DoR, PFS, and OS for up to 4 years

CONTACT: ClinicalTrialDisclosure@bms.com

CC-220-DLBCL-002

A Phase 1b/2 Randomized, Multicenter, Open-Label Study of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy for Subjects With Relapsed or Refractory Aggressive B-Cell Lymphoma[2]

Enrolling soon — *NCT04882163* — *Phase 1b/2*

PRIMARY ENDPOINTS
MTD, RP2D, and ORR

SELECT SECONDARY ENDPOINTS
Incidence of AEs, CRR, TTR, DoR, PFS, OS, PK, best ORR, HRQoL

KEY ELIGIBILITY CRITERIA

Aggressive BCL according to 2016 WHO classification among the following subtypes:

- DLBCL, NOS (including GCB and ABC types)
- High-grade BCL, with *MYC* and *BCL2* and/or *BCL6* rearrangements
- Primary mediastinal (thymic) large B-cell lymphoma
- Primary cutaneous DLBCL, leg type
- *ALK*+ large BCL
- EBV+ DLBCL, NOS
- Grade 3b FL

≥2 prior lines of therapy, or ≥1 prior line of therapy and ineligible for ASCT

Previous treatment with CAR-T therapy allowed if >5 half-lives or >4 weeks prior to starting CC-220

ECOG PS ≤2

TREATMENT *Estimated N=252*



FOLLOW-UP

Follow up for adverse events until ≥28 days after last dose of study treatment, ORR for up to 6 years, and CRR, TTR, DoR, PFS, OS, and HRQoL for up to 7 years

CONTACT: ClinicalTrialDisclosure@bms.com

The safety and efficacy of iberdomide (CC-220) and CC-99282 and/or their uses are under investigation and have not been established.
There is no guarantee that iberdomide (CC-220) and CC-99282 will receive health authority approval or become commercially available in any country for the uses being investigated.

ABC, activated B-cell; **AE**, adverse event; **ALK**, anaplastic lymphoma kinase; **ASCT**, autologous stem cell transplant; **BCL**, B-cell lymphoma; **CMRR**, complete metabolic response rate; **CRR**, complete response rate; **CT**, computed tomography; **DLBCL**, diffuse large B-cell lymphoma; **DoR**, duration of response; **EBV**, Epstein-Barr virus; **ECOG PS**, Eastern Cooperative Oncology Group performance status; **FDG**, fluorodeoxyglucose; **FL**, follicular lymphoma; **GCB**, germinal center B-cell; **HRQoL**, health-related quality of life; **IPI**, International Prognostic Index; **MRI**, magnetic resonance imaging; **MTD**, maximum tolerated dose; **NOS**, not otherwise specified; **ORR**, overall response rate; **OS**, overall survival; **PFS**, progression-free survival; **PK**, pharmacokinetics; **R**, randomized; **R-CHOP**, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; **RP2D**, recommended Phase 2 dose; **TTR**, time to response; **WHO**, World Health Organization.

1. ClinicalTrials.gov. NCT04884035. Accessed May 12, 2021. **2.** ClinicalTrials.gov. NCT04882163. Accessed May 11, 2021.